Dutasteride
- Generic Name
- Dutasteride
- Brand Names
- Avodart, Jalyn
- Drug Type
- Small Molecule
- Chemical Formula
- C27H30F6N2O2
- CAS Number
- 164656-23-9
- Unique Ingredient Identifier
- O0J6XJN02I
- Background
Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary hormonal mediato...
- Indication
Indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for BPH-related surgery alone or in combination with tamsulosin.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Symptomatic benign prostatic hyperplasia (BPH)
- Associated Therapies
- -
Economic Analyses of the REDUCE Trial
- Conditions
- Interventions
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01337258
AVODART(Dutasteride) Post-marketing Surveillance(PMS)
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3977
- Registration Number
- NCT01299571
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Dutasteride for the Reduction of Alcohol Use in Male Drinkers
- Conditions
- Interventions
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- UConn Health
- Target Recruit Count
- 47
- Registration Number
- NCT01262287
- Locations
- 🇺🇸
University of Connecticut Health Center, Farmington, Connecticut, United States
ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
- Conditions
- Interventions
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2014-03-31
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 46
- Registration Number
- NCT01215292
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Dutasteride in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- University College London Hospitals
- Target Recruit Count
- 42
- Registration Number
- NCT01193855
- Locations
- 🇬🇧
University College of London Hospitals, London, England, United Kingdom
AVODART® Alopecia Post-marketing Surveillance (PMS)
- First Posted Date
- 2009-10-30
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 712
- Registration Number
- NCT01004809
- Locations
- 🇰🇷
GSK Investigational Site, Daejeon, Korea, Republic of
Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 16
- Registration Number
- NCT00985738
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
Metabolic Effects of Steroids in Obese Men
- Conditions
- Interventions
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2011-03-16
- Target Recruit Count
- 57
- Registration Number
- NCT00983554
- Locations
- 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸VA San Diego Healthcare System, San Diego, California, United States
Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT00953576
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ARI103094-Follow-Up Study for REDUCE Study Subjects
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2795
- Registration Number
- NCT00883909
- Locations
- 🇬🇧
GSK Investigational Site, Waterloo, Liverpool, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.